Related Experiment Video
Updated: Jan 20, 2026

Generation of Induced-pluripotent Stem Cells Using Fibroblast-like Synoviocytes Isolated from Joints of Rheumatoid Arthritis Patients
Published on: October 16, 2016
Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among
Polina Putrik1, Sofia Ramiro2,3, Francis Guillemin4
1Internal Medicine, Division of Rheumatology, Maastricht University, CAPHRI and Maastricht University Medical Center (MUMC), Maastricht, The Netherlands polina.putrik@gmail.com.
Objectives:
To describe and explore differences in formal regulations around sick leave and work disability (WD) for patients with rheumatoid arthritis (RA), as well as perceptions by rheumatologists and patients on the system's performance, across European countries.
Methods:
We conducted three cross-sectional surveys in 50 European countries: one on work (re-)integration and social security (SS) system arrangements in case of sick leave and long-term WD due to RA (one rheumatologist per country), and two among approximately 15 rheumatologists and 15 patients per country on perceptions regarding SS arrangements on work participation. Differences in regulations and perceptions were compared across categories defined by gross domestic product (GDP), type of social welfare regime, European Union (EU) membership and country RA WD rates.
Results:
Forty-four (88%) countries provided data on regulations, 33 (75%) on perceptions of rheumatologists (n=539) and 34 (77%) on perceptions of patients (n=719). While large variation was observed across all regulations across countries, no relationship was found between most of regulations or income compensation and GDP, type of SS system or rates of WD. Regarding perceptions, rheumatologists in high GDP and EU-member countries felt less confident in their role in the decision process towards WD (β=-0.5 (95% CI -0.9 to -0.2) and β=-0.5 (95% CI -1.0 to -0.1), respectively). The Scandinavian and Bismarckian system scored best on patients' and rheumatologists' perceptions of regulations and system performance.
Conclusions:
There is large heterogeneity in rules and regulations of SS systems across Europe in relation to WD of patients with RA, and it cannot be explained by existing welfare regimes, EU membership or country's wealth.
Related Concept Videos
Bioavailability Study Design: Healthy Subjects Versus Patients
Patient-centered Care
Drug Dosing: Obese Patients
Drug Dosing: Geriatric Patients
Intellectual Disability
Learning Disabilities
Dyslexia
Dyslexia is a...

